Below you will find the technology offerings at the moment. Clicking on each offer you can access it to all relevant information:
The invention relates to a new drug delivery system for the selective treatment of aggressive tumours and metastatic cells. Such system is based on protein nanoparticles capable of targeting cancer cells and internalizing the therapeutic cargo inside the cell. Nanoparticles are generated by the addition of a T22 peptide to a scaffold protein, forming self-assembling nanoparticles in which the drug is further accommodated. The key point is that T22 has also the ability to internalize efficiently target cells after binding to CXCR4 receptor.
Different types of cancer: CXCR4 is overexpressed in cancer stem cells, primary tumours and metastasis-initiating cells in colorectal cancer, pancreatic cancer, glioblastoma, acute myeloid leukaemia, among other cancers.
Technology co-developed by Institut de Recerca Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona and CIBER.
From Sant Pau: Dr. Ramon Mangues (Oncogenesis and Antitumour Drugs)
We are currently testing the performance of the nanoparticle with a covalent bond with a very strong antimitotic toxin.
European patent EP20120704711
Priority date: 13/01/2011
Technology out-licensing for development and commercialization
Its innovative character is based on the combination of the properties of physical trainers, realism, and the virtual, flexible and objective assessment.
The technology incorporates a number of features that improve existing alternatives, as it allows:
Training in laparoscopy surgery, in general. Training in hysteroscopy, cystoscopy and arthroscopy, in particular.
Technology co-developed by Institut de Recerca Hospital de la Santa Creu i Sant Pau, Institut de Bioengineryia de Catalunya (IBEC) and Universitat Politècnica de Catalunya (UPC).
From Sant Pau: Dr. Ramon Rovira (Reproductive Health).
Functional prototoype of hysteroscopy simulator fully developed.
Spanish patent 2534140_B1. Granted.
Priority Date: 16/10/2013
Spanish patent P201531796. Filed.
Priority Date: 11/12/2015
The present invention provides an in vitro method for predicting risk to develop recurrence in a patient suffering from endometrial carcinoma. In particular, the method allows to readily detect patients with a high risk to develop recurrence independently of the FIGO stage and/or histology grade. The method has potential applications in optimizing the clinical management of endometrial carcinoma, with a special interest in the early stages of disease.
Risk prediction of recurrence in endometrial carcinoma
Last update: 20 de September de 2016